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Abstract
YopH is an exceptionally active tyrosine phosphatase that is essential for virulence of Yersinia pestis, the bacterium causing
plague. YopH breaks down signal transduction mechanisms in immune cells and inhibits the immune response. Only a few
substrates for YopH have been characterized so far, for instance p130Cas and Fyb, but in view of YopH potency and the
great number of proteins involved in signalling pathways it is quite likely that more proteins are substrates of this
phosphatase. In this respect, we show here YopH interaction with several proteins not shown before, such as Gab1, Gab2,
p85, and Vav and analyse the domains of YopH involved in these interactions. Furthermore, we show that Gab1, Gab2 and
Vav are not dephosphorylated by YopH, in contrast to Fyb, Lck, or p85, which are readily dephosphorylated by the
phosphatase. These data suggests that YopH might exert its actions by interacting with adaptors involved in signal
transduction pathways, what allows the phosphatase to reach and dephosphorylate its susbstrates.
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Introduction
Yersinia pestis, the bacterium responsible for plague, has caused
devastating pandemics in the past [1,2]. The bubonic plague is
transmitted to humans by blood-sucking fleas infected from animal
reservoirs, mostly rats and other rodents [3]. Once in the
organism, Yersinia presents tropism for lymphoid tissue, where
the bacterium proliferates rapidly in the extracellular space,
avoiding the host immune system and causing an intensive
lymphadenitis within 2 to 6 days [1,2]. Another variant, the
pneumonic plague, is caused by inhaled bacteria. This less usual
and even more dangerous form of plague is difficult to treat and
often results in death [4]. Although there are several treatments
available, such as vaccines [5,6] and antibiotics, they are not very
effective, especially against pneumonic plague. Moreover, Y. pestis
has started to be considered as a potential tool for bioterrorism due
to its rapid replication and effective-immune evading ability.
Y. pestis contains an extracromosomal 70-kb virulence plasmid
[7,8,9], which is essential for Yersinia pathogenity and encodes the
Yop (Yersinia outer proteins) effector proteins and the proteins
forming a type III secretion system. The direct injection of the
effector proteins by this secretion apparatus enables the bacterium
to survive and proliferate in the lymphoid tissues [10,11]. An
essential virulence factor of Yersinia is YopH, a 51-kd protein
tyrosine phosphatase (PTP) [12,13] with a C-terminal catalytic
domain that shares structural similarities to that of eukaryotic
PTPs [14], followed by a Pro-rich sequence and a multifunctional
N-terminal domain, which binds tyrosine phosphorylated target
proteins [15,16]. Bacterial injection of YopH into phagocytic cell
types causes the inhibition of the inflammatory response of the
host to the bacteria by processes such us disruption of focal
adhesions [17,18] and inhibition of phagocytosis [19,20], tumor
necrosis factor a release, and oxidative burst [21,22]. YopH also
impairs T and B lymphocyte function [23] at very early stages
preventing a successful adaptive immune response which is crucial
for the survival of the bacteria in the lymph nodes of the infected
host. Several proteins have been identified as YopH substrates in
different cell types. In epithelial cells, the adaptors p130Cas
(p130Crk-associated substrate) and paxilin, and the tyrosine kinase
FAK (focal adhesion kinase). In macrophages, p130Cas, Fyb (Fyn
binding protein) [24], SKAP-HOM (SKAP55 homologue) [25],
and Pyk, a tyroine kinase homologous of FAK. And in T-cells,
Lck, LAT, and SLP-76 [26,27]. The majority of these proteins fall
in two classes: tyrosine kinases and adaptors. Notably, these
proteins participate in pathways involved in phagocytosis and
activation of signal transduction in the early stages of the immune
response in haematopoietic cells.
Given the complex nature of the signalling pathways activated
in the immune responses and the numerous proteins involved, we
hypothesized that to inhibit the immune response with such
potency, YopH should have a wide specificity so it could target a
broad range of proteins. As a first approach to identify new YopH
substrates, we planned biochemical experiments to demonstrate
these interactions. Our results showed that YopH binds p85,
Gab1, Gab2, and Vav, although, YopH only dephosphorylated
p85. In this sense, we proposed that binding to the adaptors Gab1,
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complexes are formed. By targeting these complexes, YopH
impairs the adequate immune response by the host. The findings
here described will help understand the molecular mechanisms
dependent on YopH that are used by Yersinia pestis to evade the
immune system.
Results and Discussion
YopH interacts with several proteins involved in
signalling pathways
YopH blocks the host immune response by targeting several
signalling pathways involved in activation of immune cells. This
highly active bacterial PTP inhibits phagocytosis, oxidative burst
associated with this process in macrophages and neutrophils, Ca
2+
signalling in neutrophils, and antigen induced activation of
lymphocytes[28]. Integrin signalling initiated by binding of
Yersinia invasion to b1-integrin in the host cells, as well as
antigens through TCR (T-cell receptor) in lymphocytes, depend
on the activation of tyrosine kinases that phosphorylate a great
number of substrates involved in those pathways. Given the
potency of YopH to shut down these signalling pathways, we
considered that YopH could target additional proteins not
identified as yet. Having this in mind, we check by biochemical
methods the interaction of YopH with several signalling proteins
known to be expressed in hematopioetic cells. Thus, we expressed
several proteins in HEK293 cells and treated them with
pervanadate to induce their tyrosine phosphorylation. Lysates
were used in pull-down assays with 2 or 5 mg of a GST fusion
protein of YopH substrate trapping mutant, GST-YopH D356A.
We assayed several proteins for interaction with YopH, mainly
tyrosine kinases like Lck, Fyn, Csk, Zap-70, Syk and the regulatory
subunit of the PI3K, p85; and adaptors such as Gab1, Gab2, Cbl,
Fyb, Vav, and Grb2. We used Fyb and Lck as positive controls in
these assays, because they have been shown before to bind YopH
[24,26]. In our assays, GST-YopH D356A bound Fyb, Gab 1,
Gab 2, Lck, Vav and p85 (Fig. 1 A), while it did not bind the rest
of the proteins tested (data not shown). Some of those proteins,
LAT and Zap-70, have been shown to interact with YopH but we
have not been able to observe this association. Differences between
our data and those of Gerke et al. [27] could be explain by the
different technical approach used, pull-down versus immunipre-
cipitation of Yersinia infected T-cells. An alternative explanation is
also possible; the presence of those proteins in the precipitates
could be due to indirect interaction with other proteins present in
T-cells.
Although binding of these proteins to YopH was expected to be
mediated by tyrosine phosphorylation, we confirmed this finding
with another experiment in which the pull-down assay was carried
out with lysates from transfected HEK293 cells treated and left
untreated with pervanadate. As hown in Fig. 1.B, interaction
between YopH DA (D356A) is mainly detected when proteins are
phosphorylated on tyrosine. Only a slight interaction is observed
in the case of two proteins, Lck and Vav, in absence of
pervanadate, which it is probably due to the presence of some
phosphorylated tyrosine in the resting state, as it is the case of Lck
Y505.
YopH interacting proteins are not only substrates but
also adaptor proteins
To demonstrate that the proteins that bound YopH were
substrates of this phosphatase we carried out dephosphorylation
assays in vitro with recombinant GST-YopH produced in bacteria
using as control the inactive substrate trapping mutant GST-
YopH D356A. Contrary to our expectations, Gab1, Gab2 and
Vav were not dephosphorylated, even with incubations as long as
1 hour (Fig. 2A). On the other hand, as it has been shown before,
Lck and Fyb were dephosphorylated [24,26], although in the case
of Lck, with a lower efficiency. In this assay, we also detected p85
dephosphorylation by YopH, with almost the same efficiency than
Fyb. These data support the notion that YopH shows selectivity
for some proteins as demonstrated by other researchers [19,29].
Furthermore, we show that YopH is able to bind to some adaptor
proteins without dephosphorylating them, thus YopH could
associate with immune signalling complexes and, in this way, be
localized to the proximity of its substrates to dephosphorylate
them.
Different YopH domains are involved in the interaction
with the target proteins
YopH binds tyrosine phosphorylated proteins through two
domains, the N-terminal domain (amino acids 1–129) and the
catalytic domain (amino acids 193–468), which presents two
interaction sites, the catalytic pocket and a second site on the
opposite side of this domain [30]. Between these sites, there is a
Pro-rich region (PRR) that may bind to SH3 domains. To analyze
the interaction of YopH with the proteins studied here and based
on this domain structure and on the biochemical data related to
YopH substrate interaction, we generated four deletion mutants of
YopH: N129 (amino acids 1–129), N220 (amino acids 1–220),
C339 (amino acids 129–468), and C277 (amino acids 193–468)
(Fig. 3 A). These peptides were used as GST-fusion proteins in
pull-down assays using lysates from pervanadate stimulated cells.
Using this approach, we observed that Fyb, a well-known YopH
substrate, binds YopH through the N129 and the catalytic
domain. Gab1 and Gab2 also bind through both domains but
they do not bind to C227, indicating that, for binding, they
required additional amino acids present in the PRR. Taking into
account that Gab adaptors lack SH3 domain, association would
imply another mechanism not determined yet. In the case of Vav,
p85, and Lck, the stronger association was observed with the
deletion mutant C339, which contains the catalytic domain and
the Pro-rich region. All these proteins contain SH3 domains that
might interact with the YopH PRR, thus explaining why removal
of this region abrogates the interaction and why the N220
construct binds slightly to these proteins while the N129 domain
shows no binding at all. According to the data shown in Fig. 3B,
the proteins that bind to YopH can be divided into three groups: i)
proteins that interact with both the catalytic domain and the N129
domain (Fyb), ii) proteins that interact with the extended catalytic
domain, which includes PRR domain and the N129 domain
(Gab1 and Gab2), and iii) proteins that only bind to the extended
catalytic domain C339 (Lck, p85, and Vav).
YopH phosphatase domain is enough for the inhibition
of T cell activation
To determine how these deletion mutants affect signalling in
vivo, we overexpressed them in Jurkat T-cells along with reporter
plasmids that express the luciferase gene under the control of
different promoters relevant to T-cell activation: NFAT/AP1 and
NF-kB sites from the IL-2 promoter, and the minimal IL-2
promoter. In all the cases we obtained similar results (Fig. 4). N-
terminal domains did not inhibit activation of these reporters and
in the case of IL-2 promoter they even caused some increase over
the activation produced by the stimuli alone. This increase could
be due to some specific effect in which this peptide disrupts some
molecular interaction of the proteins here studied or, alternatively,
YopH Binds to Gab1&2,p85 & Vav
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C278, which contains the PTP domain, and C339, which contains
the PTP domain and the Pro-rich sequence, inhibited the
activation of the reporters with a potency similar to the one
exerted by the whole protein. These results show that a long
exposure of cells to both YopH phosphatase and its catalytic
domain inhibits activation of signal transduction pathways.
Conclusions
In this work, we show the interaction of YopH with several
proteins expressed in hematopoietic cells and involved in signalling
transduction pathways, such as the adaptor proteins Gab1, Gab2;
the guanine nucleotide exchange factor (GEF) for Rho-family
GTPases, Vav; and p85, the regulatory subunit of the PI3Kinase.
The PI3K family is involved in the innate and adaptive immune
responses. Class I PI3Ks are heterodimers containing a regulatory
subunit, of which p85 is the most common, and a p110 catalytic
subunit. This class of PI3Kinases acts downstream of receptor
tyrosine kinases activated by stimuli such as cytokines, antigen
receptors (TCR, BCR, FcR), and Toll-like receptors [31,32]. PI3K
enzymesareinvolvedinphagocytosisinitiatedbydifferentpathways
in immune cells [31], therefore inhibition of this pathway by YopH
would inhibit uptake of Yersinia. Our data showing that p85 is
targeted by YopH provides additional information about the
Figure 1. Pull-down assays with GST-YopH D356A. A, HEK293 cells expressing different proteins, either untreated (control) or treated with
pervanadate (PV) to induce tyrosine phosphorylation of the proteins expressed, were lysed and probed for interaction with GST-YopH D346A or GST
(5 mg each) as a negative control in pull-down assays. The specific interaction of those proteins with GST-YopH D356A was detected by Western blot
with specific antibodies for Lck or Vav, and with anti-HA antibody for other proteins. B, As in A, HEK293 cells, expressing the same proteins and
treated with PV, were lysed and probed for interaction with two different amounts of GST-YopH D346A (5 and 2 mg) or GST (5 mg each) as a negative
control in pull-down assays. GST and GST-YopH D346A fusion protein used in these assays are shown at the lower panel from one representative blot.
TL denotes total lysates of the transfected cells and corresponds to a 10% of the amount used for each pull-down assay. Assays were done
independently for each protein.
doi:10.1371/journal.pone.0004431.g001
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leads to the induction of MCP-1 and IL-2 cytokines in macrophages
andT cells[33],respectively.Inthisrespect,p85dephosphorylation
by YopH would impede the recruitment of monocytes, attracted by
the chemokine MCP-1, to the sites of Yersinia infection.
Gab1 and Gab2 belong to the Dos/Gab subfamily of scaffolds
and play important roles in the function of many hematopoietic
cell types. Gab1 and Gab2 are tyrosine phosphorylated upon
receptor engagement by antigens and cytokines [34]. Studies on
bone marrow–derived macrophages from Gab22/2 mice have
shown that this protein is involved in FccR-mediated phagocytosis.
Tyrosine phosphorylation of Gab1 and Gab2 after receptor
engagement allows association with p85 through its SH2 domains.
Therefore, by binding to Gab adaptors, YopH might target p85 or
other proteins recruited to the same signalling complex that quite
likely would regulate phagocytosis in the immune system. In our
hands, affinity of YopH for Gab adaptors is similar to the affinity
for another well known substrate of YopH, Fyb. This data would
indicate that in addition to binding directly to its substrates, YopH
binds to some adaptors, what would improve its ability to gain
access to substrates in signalling pathways. In other words, this
strategy would allow YopH to be at the place where signalling
complexes are formed to dephosphorylate its cognate substrates.
In addition to its function as GEF for Rho-GTPases that are
known to regulate the actin cytoskeleton, Vav may develop adaptor
like functions through the other domains present in its sequence [35].
Phosphorylation of Vav proteins has been reported in all hemato-
poietic cells downstream of immune receptors, including antigen
receptors (TCR, BCR, FceRI, FccRI/II/III), integrins, cytokine
receptors, and chemokine receptors. YopH does not dephosphorylate
Vav, what makes it likely the use of this protein by YopH to target
signalling proteins involved in activation of the cytoskeleton [36].
Our assays show that the PRR is involved in binding to most of
theproteins herestudied.Only Fybwasable to bind toalltheYopH
deletion mutants, in particular, it is the only protein that bound
clearly to the catalytic domain, C278. Then, YopH is able to bind
Fybphosphorylatedtyrosineseitherthroughthecatalytic domainor
through the N129 substrate binding domain and to the Fyb SH3
domain through the PRR. Gab2 shows a slight binding to the C278
catalytic domainwhile Gab1 did not bind this peptide. The fact that
Gab proteins, which lack SH3 domains, bind to the C339 peptide
that contains the PRR in addition to the phosphatase domain
suggest that this PRR contributes notably to the interaction and this
binding might be mediated by a mechanism other than the
canonical association of SH3 domains with Pro motifs. The other 3
proteins here studied, Lck, Vav, and p85, bind mainly to YopH
through the C339 peptide and only weakly with the N220. From
our data, we can conclude than tyrosine phosphorylation is the
main requirement for YopH binding and although YopH PRR
contributes to this binding, its role is not clear at least in the case of
Gab proteins since this region increase association to YopH and
those proteins lack SH3 domains.
In summary, herein we present biochemical data supporting the
interaction of the Yersinia phosphatase YopH with Gab1, Gab2,
Vav, and the p85 regulatory subunit of PI3K. Only p85 was
dephosphorylated by YopH, suggesting that the other proteins are
used by YopH to target signalling complexes in the immune cells.
These results, here presented, broaden the knowledge about
substrate repertoire of YopH and help to understand YopH
inhibitory potency on cell host signalling pathways.
Materials and Methods
Antibodies and reagents
Tissue culture reagents were from Cambrex (Verviers, Belgium).
The 12CA5 anti-hemagglutinin (HA) monoclonal antibody (Ab)
was from Roche (Indianapolis, IN USA), anti-HA clone HA.11 was
from Covance (Berkely, CA USA), anti-GST (Glutathione S-
transferase) was from Santa Cruz Biotechnology Inc. (Santa Cruz,
CA USA), anti-b-actin mAb (monoclonal Ab) was from Sigma
Chemical Co. (St. Louis, MO USA). Anti-CD3 (UCHT1) and
CD28 (clone CD28.2) Ab were from BD Pharmingen (Franklin
Lakes, NJ USA). The anti-phosphotyrosine mAb 4G10 was from
Upstate Biotecnology, Inc. (Lake Placid, NY).
Plasmids and mutagenesis
Plasmids encoding HA-YopH and HA-YopH D356A and Lck
were described before [26], as well as p85 vector [37]. Fyb
expresion plasmid was kindly provided by Christopher E. Rudd,
Gab1 and Gab2 were generous gifts from Gen-Sheng Feng, and
Vav expression vector was kindly provided by Xose Bustelo.
Standard molecular biology techniques were used to generate the
different constructions used in this study. YopH deletions were
done by PCR using appropriate primers. Mutagenesis was
performed using the QuickChange site-directed mutagenesis kit
(Stratagene, San Diego, CA) as described by the manufacturer.
Figure 2. YopH dephosphorylation assay of several proteins. A, Dephosphorylation assay for HA-Gab1, HA-Gab2 and Vav at different time-
points, using 1 mg of GST-YopH or GST-YopH D356A. The assay was stopped by addition of sample buffer, and after SDS-PAGE, samples were
transferred to nitrocellulose and tyrosine phosphorylation was detected by Western blot with anti-phosphotyrosine antibody. B, Dephosphorylation
assay for HA-Fyb, Lck and HA-p85 was carried out as in A, but using shorter incubation times. Proteins used as substrates in these assays were
obtained from HEK293 transfected with the corresponding plasmids and treated with pervanadate. Proteins were immunoprecipitated and
distributed equally in different tubes for the several time-points of the assay.
doi:10.1371/journal.pone.0004431.g002
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Jurkat T leukemia cells were kept at logarithmic growth in
RPMI 1640 medium supplemented with 10% fetal bovine serum,
2 mM L-glutamine, 1 mM sodium pyruvate, nonessential amino
acids, 100 U/ml penicillin G, and 100 mg/ml streptomycin.
Transfection of Jurkat T cells was performed by electroporation
as described previously (14, 15). HEK293 were maintained at
37uC in DMEM Dulbecco’s modified Eagle’s medium supple-
mented with 10% fetal bovine serum, 2 mM L-glutamine, 100 U/
ml penicillin G, and 100 mg/ml streptomycin. For transient
transfection, HEK293 cells were transfected using the calcium
phosphate precipitation method (16).
Figure 3. Pull-down assays with different deletion mutants of YopH. A, Schematic diagram showing the different deletion mutants of YopH
used in this study. B, HEK293 cells expressing different proteins and treated with pervanadate (PV) to induce tyrosine phosphorylation of the proteins
expressed were lysed and probed for interaction with GST-YopH D/A (mutation D346A), the different deletion mutants shown in A fused to GST, and
GST (5 mg each) as a negative control in pull-down assays. The specific interaction of those proteins with YopH fragments was detected by Western
blot with specific antibodies for Lck and Vav, and with anti-HA antibody for other proteins. An independent experiment was done for each protein.
The lower panel shows a representative blot from one of the experiments to show that similar amounts of GST proteins were used in these assays.
doi:10.1371/journal.pone.0004431.g003
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immunoblotting
These procedures were done as reported before (14). Briefly, cells
were lysed in lysis buffer: 20 mM Tris/HCl, pH 7.5, 150 mM
NaCl, 5 mM EDTA containing 1% NP-40, 1 mM Na3VO4,
10 mg/ml aprotinin and leupeptin, and 1 mM phenylmethylsul-
phonyl fluoride. Lysates were clarified by centrifugation at
15,000 rpm for 10 min. The clarified lysates were preabsorbed on
protein G-Sepharose (GE Healthcare) and then incubated with
antibody for 2 h, followed by overnight incubation with protein G-
Sepharose beads. Immune complexes were washed three times in
lysisbufferandresuspended inSDSsamplebuffer.Proteins resolved
by SDS-PAGE were transferred to nitrocellulose membrane, which
were immunoblotted with optimal dilutions of specific Abs followed
by the appropriate anti-IgG-peroxidase-conjugate. Blots were
developed by the enhanced chemiluminescence technique (ECL
kit, GE Healthcare) according to the manufacturer’s instructions.
Pull-down of GST fusion proteins was done with Glutathione-
Sepharose beads (GE Healthcare) incubated with the clarified
lysates for 2 hr. Then the complexes were washed and processed as
explained above for the immunoprecipitation.
In vitro dephosphorylation assay
HEK293T cells were transfected with the indicated plasmids to
produce the proteins used as substrates and cells were treated with
pervanadate to induce tyrosine phosphorylation of proteins. Cells
were lysed in lysis buffer and the clarified lysates were
immunoprecipitated with the appropriate antibodies. Washed
immunocomplexes were incubated with 1 mg of YopH or YopH
D356A at 4uC during the indicated times. Dephosphorylation of
proteins in the immunocomplexes was detected by Western blot
using the 4G10 antibody.
Luciferase Assays—Transfection of Jurkat T cells and assays
for luciferase activity were performed as described previously (28–
30). Briefly, 20610
6 Jurkat cells were transfected with 10 mg empty
pEF5HA vector alone or YopH plasmids, along with 2 mgo f
NFAT/AP-1-luc (or other reporters) and 1 mgo faRenilla
luciferase reporter for normalization. Cells were stimulated with
anti-TCR plus anti-CD28 antibodies 24 hr after transfection for
the last 6 hr. Cells were lysed then and processed to measure the
luciferase activity with the Dual Luciferase system (Promega)
according to the manufacturer’s instructions.
Statistics—For statistical analysis of data, unpaired Student’s t
test was performed (PRISM version 4.0; GraphPad) as appropri-
ate. Values of p,0.05 were considered significant.
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